D2Rs Agonist Ropinirole Cooperates with Metformin to Modulate Thermogenesis and Ameliorate Obesity-Related Metabolic Disorders in Mice
Diabetes & Metabolism Journal · 01.11.2026 · 50 (6) · 1149-1165
DOI: 10.4093/dmj.2025.0335 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes & Metabolism Journal, erschienen am 01.11.2026. Verfasst von Bangrui Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education and Yunnan Key Laboratory of Research and Development for Natural P…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Metabolic disorders represent a significant challenge to human health, primarily due to their widespread prevalence and the limited availability of alternative pharmacological interventions. Drug repurposing offers a promising and expedited strategy to address these conditions.
Methods
To elucidate the efficacy and underlying mechanism of the combination of metformin with ropinirole on anti-obesity and obesity-related metabolic disorders.
Results
The results indicate that the combination treatment led to a significant reduction in body weight and improvements in hyperglycemia, dyslipidemia, and insulin resistance. These enhancements, along with increased energy expenditure, were significantly greater than those achieved with either drug alone. Additionally, we observed the browning of inguinal white adipose tissue (iWAT) and alterations of the whitened-brown adipose tissue (BAT), along with substantial increases in mitochondrial function-related proteins. However, the drug combination did not exhibit any enhanced effect on cell thermogenesis and these proteins in vitro, whereas combination of norepinephrine and metformin-induced an additive upregulation of mitochondrial function-related proteins. Furthermore, pharmacological blockade of the β3 adrenergic receptor inhibited the energy expenditure induced by the combination treatment, etc.
Conclusion
Our study underscores the combination of metformin and ropinirole-induced an amplified effectiveness in treating obesity-related metabolic disorders is dependent on the dopamine-control sympathetic nerve activity, and metformin acts directly on BAT and iWAT to improve mitochondrial function, which offering a new perspective for future clinical co-treatment of metabolic disorders with these two drugs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education and Yunnan Key Laboratory of Research and Development for Natural Products, School of Pharmacy, Yunnan University, Kunming, China.
- School of Life Science, Yunnan University, Kunming, China.
- State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China.
- University of Chinese Academy of Sciences, Beijing, China.
Zitieren
APA
Huang, B., Liu, D., Jiang, F., Wang, Z., Mao, C., Lu, Q., Chen, T., Xie, C., Chen, W., Wang, Q., & Xiong, W. (2026). D2Rs Agonist Ropinirole Cooperates with Metformin to Modulate Thermogenesis and Ameliorate Obesity-Related Metabolic Disorders in Mice. Diabetes & Metabolism Journal, 50(6), 1149-1165. https://doi.org/10.4093/dmj.2025.0335
Vancouver
Huang B, Liu D, Jiang F, Wang Z, Mao C, Lu Q, et al. D2Rs Agonist Ropinirole Cooperates with Metformin to Modulate Thermogenesis and Ameliorate Obesity-Related Metabolic Disorders in Mice. Diabetes & Metabolism Journal. 2026;50(6):1149-1165. doi:10.4093/dmj.2025.0335
BibTeX
@article{Huang2026,
author = {Huang, Bangrui and Liu, Daowei and Jiang, Fakun and Wang, Zihui and Mao, Chuanjun and Lu, Qian and Chen, Tao and Xie, Chun and Chen, Wenli and Wang, Qian and Xiong, Wenyong},
title = {D2Rs Agonist Ropinirole Cooperates with Metformin to Modulate Thermogenesis and Ameliorate Obesity-Related Metabolic Disorders in Mice},
journal = {Diabetes & Metabolism Journal},
year = {2026},
volume = {50},
number = {6},
pages = {1149--1165},
doi = {10.4093/dmj.2025.0335}
}
EUVIMED